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Abstract
Is there a role for sentinel lymph node (SLN) biopsy in the management of sarcoma? Sentinel node biopsy has dramatically
changed the management of melanoma and breast cancer, helping surgeons avoid radical lymphadenectomies in node negative
patients who would previously have undergone a more morbid operation with little benefit, or remained pathologically unstaged.
Many investigators have explored the use of lymphatic mapping for malignancies other than breast cancer or melanoma. Lymphatic
mapping and sentinel node biopsy has not been investigated in the management of sarcomas, which is not surprising given that the
majority of sarcomas spread by local extension or hematogenously. Regional lymph node metastases are rare; developing in about
3–10% of patients with localized disease. However, among certain subtypes of high-grade sarcomas there is a propensity for regional
lymph node metastases. These include rhabdomyosarcoma, epithelioid sarcoma, clear cell sarcoma, synovial sarcoma, and vascular
sarcomas. It is in these particular subtypes that there may be a benefit to SLN biopsy.
r 2003 Elsevier Ltd. All rights reserved.
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1. Introduction
The use of sentinel lymph node (SLN) biopsy to assess
the regional lymphatic basin for the presence of
metastatic disease is quickly becoming the standard of
care in the management of melanoma and breast cancer.
The concept of lymphatic mapping and SLN biopsy was
first described by Cabanas in 1977 in regards to penile
cancer [1]. The concept was further developed by
Morton, who reported its use for melanoma in 1992
[2]. The core concept behind the sentinel node is that the
primary tumor reliably drains to one or a few lymph
nodes in the regional lymphatic basin, and therefore
histopathologic analysis of these ‘‘sentinel’’ nodes
reflects the disease status of the entire lymphatic field.
Several studies have supported this hypothesis in both
melanoma [3–5] and breast cancer [6–8]. In utilizing
SLN biopsy to stage the regional lymphatic basin,
surgeons hope to avoid radical lymphadenectomies node
negative patients who would previously have undergone
a more morbid operation with little benefit, or remained
pathologically unstaged.
Given the potential advantages of SLN biopsy, many
investigators have explored the use of lymphatic
mapping for malignancies other than breast cancer or
melanoma. These include lung cancer [9], colon cancer
[10,11], squamous cell carcinoma of the head and
neck [12,13], gynecologic cancers [14–16], thyroid cancer
[17,18], Merkel cell carcinoma [19–21], upper gastro-
intestinal cancers [22,23] and non-small cell lung cancer
[24]. Though its role has yet to be defined, surgeons are
hoping this minimally invasive technique may serve as a
means to improve staging, better predict prognosis and
utilize adjuvant therapies and decrease morbidity by
avoiding unnecessary major lymphadenectomies.
One malignancy for which SLN biopsy has not been
investigated is sarcoma. That the technique of SLN
biopsy has not been investigated in the management of
sarcomas is not particularly surprising given that the
majority of sarcomas spread by local extension or
hematogenously. Regional lymph node metastases are
rare; developing in about 3–10% of patients with
localized disease [25]. Recurrence in the regional nodal
basin is also rare, representing 4–10% of recurrences,
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often with distant metastases as well [26,27]. Classic
teaching in sarcoma stresses radical excision of the
primary without need for lymph node evaluation or
lymphadenectomy. Though the overall incidence of
regional lymph node metastases in sarcoma is low, there
do appear to be certain histologic subtypes in which
there is an increased incidence. Skinner and Eilber
reviewed a number of different studies demonstrating
the increased incidence of regional lymph node metas-
tases in certain types of sarcomas [25]. They concluded
that lymph node metastases occurred almost exclusively
in high-grade lesions. Among high-grade sarcomas, only
certain subtypes such as rhabdomyosarcoma, epithelioid
sarcoma, clear cell sarcoma, synovial sarcoma, and
vascular sarcomas appeared to have a propensity for
regional lymph node metastatic spread. It is in these
particular subtypes that benefits of SLN biopsy might be
realized. In this mini-review for Surgical Oncology, we
present an argument for the selective use of SLN biopsy
in the management of sarcoma.
2. Rhabdomyosarcoma
Rhabdomyosarcoma, sarcomas with demonstrated
skeletal muscle differentiation, are common in children
and rare in adults. Rhabdomyosarcoma demonstrated
regional lymph node metastasis in 11–36% of cases
[25,28–30]. As such, it is clearly one of the histologic
types of sarcoma with a higher than average likelihood
of regional nodal involvement. It is also the only
histologic type of sarcoma for which regional nodal
treatment is commonly considered as part of initial
therapy.
2.1. Pediatric rhabdomyosarcoma
SLN biopsy is likely to ultimately prove to be
beneficial in the initial management of pediatric
rhabdomyosarcoma. Rhabdomyosarcoma is the most
common soft tissue sarcoma in children under 15 years
of age and is the sixth most common form of cancer in
childhood. Pediatric rhabdomyosarcoma is clearly a
responsive tumor, with defined roles for adjuvant
therapy with radiation and systemic chemotherapy.
There are several sites where these tumors preferentially
occur. Rhabdomyosarcomas originating in the extremi-
ties and the genitourinary tract appear to be particularly
associated with regional lymphatic spread. One review
found that the percentage of patients with nodal
metastases from extremity lesions was 12% [31]. The
presence or absence of regional lymphatic spread in
extremity lesions was a significant prognostic factor in 3-
year survival rates in these patients. A follow-up study
confirmed the necessity of surgically evaluating lymph
node basins in extremity rhabdomyosarcoma in order to
more accurately stage patients, with the ultimate hope of
using improved staging to develop optimal risk-based
therapies [32]. Performing SLN biopsy in these children
may assist oncologists in projecting survival for these
children while at the same time preventing unnecessary
major lymphadenectomies. Those with positive SLNs
could undergo completion lymphadenectomy, and be
treated systemically as for clinically node-positive
disease.
In the case of rhabdomyosarcoma of the genitour-
inary tract in children, regional lymphatic spread has
been reported in up to 24% of children with this type of
disease [31]. As with pediatric rhabdomyosarcoma of the
extremities, understanding the nodal status in these
patients directly impacts therapy. Patients with known
nodal disease of the regional lymphatic basin in
rhabdomyosarcomas of the bladder, prostate, vagina/
uterus, and paratesticular tissues routinely undergo
systemic chemotherapy and radiation therapy to the
regional lymphatic basin [33].
The evolving management of paratesticular rhabdo-
myosarcoma over the past 2 decades is especially
illustrative of the potential benefit of SLN biopsy in
the management of pediatric genitourinary rhabdomyo-
sarcoma. Initially, all patients with paratesticular
rhabdomyosarcoma required ipsilateral retroperitoneal
lymph node dissection. Subsequently, the Intergroup
Rhabdomyosarcoma Study Group recommended clin-
ical evaluation of retroperitoneal lymph nodes using
computerized tomography [34]. Only those patients with
suspicious lymph node involvement on CT scan under-
went surgical evaluation of the lymph node basin.
Comparison of these two approaches suggested that
reliance on CT scan evaluation of the regional lymph
node basin resulted in understaging of lymphatic spread
and resulted in underutilization of effective adjuvant
therapy [34]. Developing SLN protocols seems a very
appealing technology as a means to avoid the morbidity
of retroperitoneal lymph node dissection in those
patients with clinically localized disease.
Of course, techniques for identifying sentinel nodes
from genitourinary tract primaries are far less developed
than those for tumors arising on the extremities and
trunk. Given the focus of pediatric oncologists on
treating rhabdomyosarcoma patients in nationwide
clinical trials, prospective evaluation of SLN biopsy in
this disease seems feasible and worthwhile, but may
require new approaches not routinely used when SLN
biopsy is performed for other tumor types.
2.2. Adult rhabdomyosarcoma
In contrast to the pediatric population, the literature
describing adult rhabdomyosarcoma is limited, reflect-
ing its rarity and the paucity of prospective trials in
adult sarcomas. The prognosis for adults diagnosed with
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rhabdomyosarcoma is poor—worse than pediatric
sarcomas and worse than other adult soft tissue
sarcomas of comparable stage and grade. In one series,
the overall 5- and 10-year survival rate for patients
diagnosed with rhabdomyosarcoma was 31% and 27%,
respectively [35]. Relatively little is known about the
frequency and prognostic impact of nodal status in adult
patients treated with multimodality therapy. Hence,
while SLN biopsy in adult rhabdomyosarcoma appears
to merit prospective evaluation, its overall impact on the
disease is likely to be small at best.
3. Epithelioid sarcoma
Epithelioid sarcoma is a rare high grade soft tissue
sarcoma that presents most commonly in adult males in
their 20s and 30s and occurs almost exclusively in the
extremities. Because of an innocuous presentation,
diagnosis is often delayed. Five- and ten-year overall
survival is 70% and 42%, respectively [36]. Epithelioid
sarcoma clearly has a propensity for regional lymphatic
spread [37]. Regional lymph node metastases in these
patients ranges from 17% to 80% [25,28–30]. A more
recent report demonstrated regional lymph node metas-
tases during the course of the disease to be 44% [38].
Lymphatic spread has been shown to be an independent
prognostic factor in predicting survival rates for these
patients [39].
With conservative surgery, nodal failure rate ranges
between 19% and 44% [38,40,41]. However, nodal
failures are often associated with distant metastases,
suggesting that nodal failures represent a component of
widespread dissemination rather than a purely locor-
egional event. Routine treatment of the nodal basin,
either by surgery or irradiation, appears unlikely to
benefit these patients [38,42]. With such a high incidence
of regional spread though, evaluation of the regional
lymph node basin by lymphatic mapping and SLN
biopsy may be an excellent strategy for selecting those
patients who might benefit from lymphadenectomy or
early systemic therapy [40].
4. Clear cell sarcoma
Clear cell sarcoma, often referred to as malignant
melanoma of the soft parts, has a distinct behavior from
other sarcomas—including a tendency to nodal recur-
rence and widespread metastasis throughout the body.
In its pattern of spread, it more closely resembles
melanoma than sarcoma, hence the alternate name
melanoma of soft parts. It is a rare tumor constituting
1% of all soft tissue sarcomas, with only about 300 cases
having been described in the literature to date [43]. It
arises most commonly in the extremities as a bulky,
locally invasive tumor. As such, it is a logical candidate
for SLN biopsy.
The incidence of lymph node metastases in clear cell
sarcoma range from 25% to 50% [25,43]. Complete
surgical excision is the standard of care in the manage-
ment of clear cell sarcoma. The role of adjuvant
chemotherapy and radiation therapy has yet to be
determined. At this time, tumor size has been the only
feature to predict tumor recurrence, with tumors greater
than 5 cm demonstrating a high incidence of metastatic
spread. Currently, those patients with tumor size >5 cm
undergo some form of adjuvant therapy, primarily
doxorubicin-based chemotherapy [43]. However, be-
cause this sarcoma is so rare, it has been difficult to
sort out optimal clinical management. With 5-, 10-, and
20-year survival of 67%, 33%, and less than 10%,
respectively, there is work to be done to better manage
this rare sarcoma [43]. The addition of SLN biopsy to
the management of clear cell sarcoma could be a
valuable technique to better predict prognosis and to
further refine adjuvant therapy. Equally important
will be ongoing biologic studies to better define the
origin and nature of this rare tumor, in order to
determine if it should be treated like a sarcoma or a
melanoma [44].
5. Synovial sarcoma
Synovial sarcomas account for 7–8% of all soft tissue
sarcomas and are the most common non-rhabdomyo-
sarcoma soft tissue sarcomas in pediatric patients.
Overall 5-year survival rates for patients diagnosed with
synovial sarcoma ranges from 57% to 88% [45,46].
Review of the literature demonstrates regional lympha-
tic spread between 2% and 17% of the time [25,28–30].
As such, synovial sarcoma is the most common form of
sarcoma for which regional spread is a potential clinical
concern. More than 90% of these sarcomas are found in
the extremities or trunk. In one recent report on
synovial sarcoma, the authors contend that complete
resection with clear margins and evaluation of regional
lymphatic spread is the treatment of choice for this
tumor [47]. The role of radiation and chemotherapy
continues to evolve in the management of these
sarcomas, but synovial sarcomas also appear to be
among the most responsive of adult sarcomas to
chemotherapy [48]. The addition of SLN evaluation in
the management of synovial sarcoma could possibly
refine the role of chemoradiation protocols in the future,
particularly if subgroups of synovial sarcoma with
higher rates of nodal spread could be identified. Given
the variable reports about the true incidence of regional
spread in synovial sarcoma, any evaluation of sentinel
node biopsy in this disease should clearly be done in the
context of a prospective trial.
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6. Vascular sarcoma
Vascular sarcomas include both angiosarcoma and
lymphangiosarcoma. Malignant vascular sarcomas
comprise only approximately 2% of all soft tissue
sarcomas in the adult population [49]. These highly
malignant sarcomas are rare in the adult population
and even rarer in the pediatric population. Lymph
node metastases in vascular sarcomas range from
11% to 40% [25,28–30]. A more recent study notes
regional lymphatic spread in 25% of patients with
angiosarcoma [50]. However, the potential utility of
SLN biopsy in the management of these tumors is less
likely than with other sarcomas with a propensity to
nodal spread.
Vascular sarcomas are notoriously difficult to achieve
local control and often present with disseminated
disease. In one study, 42 of 67 patients developed
recurrent local disease after definitive local excision [49].
Over half of patients with angiosarcoma presented with
metastatic disease on first admission, with 5-year
survival rates of just over 20% [49,50]. The role of
radiation therapy and chemotherapy in the management
of these tumors is uncertain and many authors report
negligible benefits with either treatment modality. While
it is feasible that SLN biopsy may have a role in
targeting cases where radiation therapy or chemother-
apy might have the most benefit, the inability to achieve
local control and the frequency of metastatic disease at
presentation make its potential utility difficult to
support.
7. Conclusion
Sentinel lymph node (SLN) biopsy has revolutionized
the management of melanoma and breast cancer, and is
beginning to be applied to other tumors with a
propensity for lymphatic spread. Although as a whole
sarcomas do not have such a propensity, certain types of
sarcomas have rates of nodal metastases comparable to
that for an intermediate thickness cutaneous melanoma
(10–20%). The sentinel node biopsy procedure has a
very low morbidity and a high likelihood of success,
particularly for extremity primaries. As with melanoma
and breast cancer, questions exist regarding the impact
of selective regional lymph node dissection on distant
relapse free survival and overall survival. In addition,
the prognostic information obtained from nodal in-
volvement of these sarcomas and the benefit of adjuvant
systemic therapy in these patients is less clear than for
other malignancies. In order to determine how best to
use this technology in the rare types of sarcoma for
which it may be ultimately useful, prospective multi-
center clinical trials should be conducted. For the vast
majority of soft tissue sarcomas, however, SLN biopsy
does not have a role to play, and its indiscriminate use
should be condemned.
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